Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Cybin Inc. CYBN

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTC: CLXPF) to Leverage Breakthrough Tech to Measure Real-Time Brain Activity During Psychedelic Experiences

Cybin (NEO: CYBN) (OTC: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently announced its collaboration with neurotech pioneer HI LLC dba Kernel. According to the update, CYBN will leverage Kernel Flow, Kernel’s breakthrough … Continue reading

Posted in Cybin Inc. CYBN | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTC: CLXPF) Announces Upcoming Conference Call, Webcast to Provide Business Update

Cybin (NEO: CYBN) (OTC: CLXPF), a life sciences company focused on psychedelic pharmaceutical therapies, has scheduled a conference call and webcast for 10 a.m. ET on Wednesday, Feb. 17, 2021. Cybin CEO Doug Drysdale will conduct the call and webcast. … Continue reading

Posted in Cybin Inc. CYBN, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) Positioned Amid Growing Acceptance, Legalization of Psilocybin

Cybin (NEO: CYBN) is a mushroom life science company focused on the pharmaceutical development of psychedelic products. Cybin’s subsidiary Serenity Life Sciences is engaged in the research and development of psilocybin-based medications. Widely referred to as magic mushrooms, Psilocybin has … Continue reading

Posted in Cybin Inc. CYBN | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) Poised to Provide Breakthrough Therapy for MDD

Cybin (NEO: CYBN), a mushroom life science company, is at the forefront of new treatments targeting major depressive disorder (“MDD”). The company is working to become the first to bring a psilocybin drug to market that targets MDD. This positions … Continue reading

Posted in Cybin Inc. CYBN | Leave a comment

Cybin Inc. (NEO: CYBN) Announces Partnership with Neurotech Pioneer to Leverage Innovative Technology for Psychedelic Therapeutics

CYBN partners with pioneer company focused on exploring, quantifying the human mindInnovative Flow technology adds exciting dimension to Cybin’s commitment to develop breakthrough treatments for mental health disordersInnovative technology opens new frontier in psychedelic therapeutics Cybin (NEO: CYBN), a life … Continue reading

Posted in Cybin Inc. CYBN | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) Announces API Synthesis of Multiple Tryptamine Derivatives

Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc., a wholly-controlled subsidiary of Cybin, has achieved the earn-out milestones for the period commencing Nov. 15, 2020, as contemplated by … Continue reading

Posted in Cybin Inc. CYBN, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) Announces Strategic Partnership with Kernel

Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, is excited to announce that it has entered into an agreement with neurotech pioneer HI, LLC dba Kernel (“Kernel”) to leverage its innovative technology, Kernel Flow (“Flow”), for … Continue reading

Posted in Cybin Inc. CYBN, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) Releases Report on Patent Filings, Therapeutics Program Development

Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, has provided an update on its patent filings. The company has eight filings, all tied to Cybin’s novel therapeutics, delivery mechanisms and treatment regiments. The patent updates noted … Continue reading

Posted in Cybin Inc. CYBN, MissionIRNewsBreaks | Leave a comment

Cybin Inc. (NEO: CYBN) R&D Sees Hope in Growing Acceptance of Psilocybin

U.S. taking actionable steps toward acceptance of psilocybinStates, individual cities have decriminalized, made use and possession of psilocybin low law-enforcement priorityMore psilocybin research being done focused on health, well-being of Americans facing a mental health crisis on epic levels Cybin … Continue reading

Posted in Cybin Inc. CYBN | Leave a comment

Cybin Inc. (NEO: CYBN) Targets Major Depressive Disorder with Breakthrough Therapy

Oregon is first state to permit supervised use of psilocybin, signaling shift in stigma CYBN entering phase 2 of clinical study of sublingual psilocybin for the potential treatment of MDD Newly discoverable data from psychedelic studies may potentially create entirely … Continue reading

Posted in Cybin Inc. CYBN | Leave a comment